Table 2.
SST+tPA Costs ($) |
tPA Costs ($) |
Δ Costs ($) (95% CI) | SST+tPA QALYs |
tPA QALYs |
Δ QALYs (95% CI)* | ICER ($ per QALY) | % Dominant |
% Dominated |
% <$50K |
|
---|---|---|---|---|---|---|---|---|---|---|
Base case | 215 781 | 238 984 | −23 203 (−56 946 to 12 933) | 6.789 | 5.046 | 1.743 (0.760–2.786) | Dominant | 90.0 | 0.0 | 100 |
Benefit in life-years | 215 781 | 238 984 | −23 203 (−56 946 to 12 933) | 9.128 | 7.920 | 1.208* (0.287–2.168) | Dominant | 89.5 | 0.1 | 99.9 |
Sensitivity analyses | ||||||||||
Historical costs | 135 876 | 127 368 | 8507 (−6565 to 23 804) | 6.789 | 5.046 | 1.743 (0.760–2.786) | 4881 | 13.8 | 0.0 | 99.9 |
No nursing home costs | 152 861 | 129 371 | 23 490 (12 960 to 34 573) | 6.789 | 5.046 | 1.743 (0.760–2.786) | 12 631 | 0.0 | 0.0 | 99.9 |
No long-term costs | 57 030 | 44 752 | 12 278 (5786 to 19 080) | 6.789 | 5.046 | 1.743 (0.760–2.786) | 7044 | 0.0 | 0.0 | 99.8 |
Benefit in DALYs | 215 781 | 238 984 | −23 203 (−56 946 to 12 933) | 7.235 | 5.156 | 2.079 (0.933–3.253) | Dominant | 90.0 | 0.0 | 100 |
Calibration factor 1 | 259 157 | 298 738 | −39 581 (−84 455 to 8897) | 8.396 | 6.306 | 2.089 (0.904–3.341) | Dominant | 95.0 | 0.0 | 100 |
Calibration factor 3 | 180 912 | 192 682 | −11 770 (−38 382 to 16 280) | 5.448 | 4.013 | 1.436 (0.622–2.273) | Dominant | 80.6 | 0.0 | 100 |
Calibration factor 5 | 149 596 | 152 580 | −2 984 (−23 325 to 18 445) | 4.200 | 3.066 | 1.134 (0.486–1.781) | Dominant | 60.4 | 0.0 | 99.8 |
CI indicates confidence interval; DALY, disability-adjusted life-years; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-years; SST, Solitaire stent thrombectomy; and tPA, tissue-type plasminogen activator.
Results in QALYs unless otherwise specified as life-years or DALYs.